US Thrombotic Thrombocytopenic Purpura (TTP) - Epidemiology Forecast to 2030

This ‘Thrombotic Thrombocytopenic Purpura (TTP) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Thrombotic Thrombocytopenic Purpura (TTP) epidemiology in the United States.

Thrombotic Thrombocytopenic Purpura (TTP) Understanding

Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy arteriolar platelet-rich thrombi that cause organ ischemia and produce neurologic abnormalities, kidney dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia (MAHA). TTP is caused by a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13. TTP can be acquired or hereditary; thus, TTP is classified according to its etiology.

TTP is classified into two types, first is Congenital TTP (cTTP), caused due to a mutation of the gene, ADAMTS13 responsible for desynthesizing, while the other is the most common form of TTP, Acquired TTP (aTTP), in which antibodies are created against ADAMTS13.

Thrombotic Thrombocytopenic Purpura (TTP) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura, Type-specific Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura, Gender-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Gender-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP), Age-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), and Age-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP), in the United States from 2018 to 2030.

Thrombotic Thrombocytopenic Purpura (TTP) Detailed Epidemiology Segmentation

• As per the publisher's analysis, the diagnosed prevalent cases of thrombotic thrombocytopenic purpura (TTP) in the United States were 6,002 in 2020.
• As per the publisher's analysis, the type-specific diagnosed prevalent cases of thrombotic thrombocytopenic purpura (TTP) in the United States showed that there were 5,401 cases of aTTP and 600 cases of cTTP in 2020.
• According to the publisher, out of 5,401 aTTP cases, there were 1,620 males and 3,781 females in the United States in 2020.
• According to the publisher, there were 270 males and 330 females diagnosed with congenital TTP (cTTP) in the US in 2020.
• Acquired TTP (aTTP) was found to be most prevalent in the patients of age group 18-40 years. Diagnosed prevalent cases of aTTP were found to be 74; 2,516; 1,924; and 888 in the age group < 18 years, 18-40 years, 41-60 years, and 60+ years, respectively in the United States, in 2020.
• Congenital TTP (cTTP) was more prominent in the 18-40 years age group. In 2020, 180; 258; 114; and 48 diagnosed prevalent cases of aTTP were found in the age groups of < 18 years, 18-40 years, 41-60 years, and 60+ years, respectively.

Scope of the Report

• The report covers the descriptive overview of Thrombotic Thrombocytopenic Purpura (TTP), explaining its causes, signs, and symptoms, and pathophysiology.
• The report provides insight into the historical and forecasted patient pool covering the United States.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for the US by Total Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura, Type-specific Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura, Gender-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Gender-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP), Age-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), and Age-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP).

Report Highlights

• 10-Year Forecast of Thrombotic Thrombocytopenic Purpura (TTP)
• United States Coverage
• Total Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura
• Type-specific Diagnosed Prevalence of Thrombotic Thrombocytopenic Purpura
• Gender-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
• Gender-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
• Age-specific Diagnosed Prevalent Cases of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
• Age-specific Diagnosed Prevalent Cases of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Key Questions Answered

• What are the disease risk, burdens, and unmet needs of Thrombotic Thrombocytopenic Purpura (TTP)?
• What is the historical Thrombotic Thrombocytopenic Purpura (TTP) patient pool in the United States?
• What would be the forecasted patient pool of Thrombotic Thrombocytopenic Purpura (TTP) in the United States?
• What will be the growth opportunities across the US with respect to the patient population pertaining to Thrombotic Thrombocytopenic Purpura (TTP)?
• At what CAGR the population is expected to grow across the US during the forecast period (2021-2030)?

Reasons to Buy

The Thrombotic Thrombocytopenic Purpura (TTP) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the US Thrombotic Thrombocytopenic Purpura (TTP) epidemiology.
• The Thrombotic Thrombocytopenic Purpura (TTP) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Thrombotic Thrombocytopenic Purpura (TTP) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States

Study Period: 2018-2030